Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349952 | PMC |
| http://dx.doi.org/10.1111/dth.15689 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paradoxical Psoriasiform Skin Eruption in Pediatric Patients with Inflammatory Bowel Disease Treated with TNFα Inhibitors.
Clin Exp Dermatol
October 2024
School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Article Synopsis
- TNFα inhibitors (TNFαI) can cause skin reactions resembling psoriasis in children with inflammatory bowel diseases (IBD), although most research focuses on adults.
- In a study involving 454 pediatric IBD patients, 12.8% developed these eruptions, with a median age of 14.1 years and an average of 15 months post-treatment initiation for eruptions to appear.
- Treatment commonly involved topical steroids, but one-third of the patients required more intense interventions, and some needed to stop TNFαI treatment altogether, highlighting the need for a collaborative treatment strategy.
Hybrid hair follicle stem cell extracellular vesicles co-delivering finasteride and gold nanoparticles for androgenetic alopecia treatment.
J Control Release
September 2024
State Key Laboratory of Advanced Drug Delivery and Release Systems, Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Jinhua Institute of Zhejiang University, Jinhua 321299, China. Electronic address:
Androgenetic alopecia (AGA) is a non-fatal disease prevalent worldwide. However, mixed efficacy has been observed among different therapies for hair regrowth in AGA patients. Thus, a nano-platform with synergistic treatments based on a hybrid extracellular vesicle encapsulating gold nanoparticles (AuNPs) and finasteride (Hybrid/Au@Fi) was constructed through membrane fusion between hair follicle stem cell (HFSC)-derived extracellular vesicles and liposomes.
View Article and Find Full Text PDFSystematic review of phenotypes and genotypes of patients with gastrointestinal defects and immunodeficiency syndrome-1 (GIDID1) (related to TTC7A).
Intractable Rare Dis Res
May 2024
APHM, Multidisciplinary Pediatrics Departement, La Timone Children's Hospital, Marseille, France.
Article Synopsis
- The study reviewed publications on patients with gastrointestinal defects and immunodeficiency syndrome-1 (GIDID1) linked to TTC7A abnormalities, analyzing their health outcomes, treatment, and genetic factors.
- Findings revealed a high mortality rate of 65.8% among 83 patients, with an average age of death at about 11.8 months; three phenotypic groups were observed, each with varying mortality rates.
- Genotype associations were identified, particularly the NS/NS and MS/MS variants, linked to specific phenotypes, while limited effective treatments were noted, indicating a need for better therapeutic strategies.
Taste disorders and alopecia in myasthenia gravis.
BMC Neurol
April 2024
Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
Background: Non-motor symptoms in myasthenia gravis (MG) are rarely confirmed. Although there are some small cohort studies, a large-systemic survey has not yet been performed.
Methods: We investigated the incidence and clinical characteristics of patients with MG who had taste disorders and alopecia using data of 1710 patients with MG enrolled in the Japan MG Registry 2021.
Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus.
Mod Rheumatol Case Rep
July 2024
Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan.
Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits Type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!